Publication
Anti-tumor activity of motesanib in a medullary thyroid cancer model.
Authors not recorded
J Endocrinol Invest2012PMID 21422803stubpubmedProvenance
- Source
- PubMed
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CIVIC-20260908-000001
Abstract
Abstract (excerpt)
Only the opening of the abstract is shown; abstract text may carry publisher copyright.
Data not yet available
No abstract stored. Read on PubMed
Linked entities
Linked entities (5)
How each link was made (MeSH, dictionary, registry reference, curation…) and whether it has been validated. Candidate links are not counted in entity statistics.
Validated 5
- cancerThyroid Gland Medullary Carcinomacivic_curation1.00
- drugMotesanibcivic_curation1.00
- geneRETcivic_curation1.00
- variantRET C634Wcivic_curation1.00
- variantRET M918Tcivic_curation1.00
Curated evidence
Evidence citing this paper (2)
civicProvenance
- Source
- CIViC — Clinical Interpretation of Variants in Cancer
- Dataset
- CIViC evidence items
- Version
- civic-2026-09-08
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Evidence
- expert curation
- License
- CC0 1.0
- PMID
- 21422803
- Run
- ING-CIVIC-20260908-000001
| Therapy | Cancer | Type | Level | Direction · significance | Rating (1–5) | Status | Evidence | Source |
|---|---|---|---|---|---|---|---|---|
| RET C634W1 | ||||||||
| Motesanib | Thyroid Gland Medullary CarcinomaALIAS | Predictive | D | Supports Resistance | 3 | accepted | EID75Medullary thyroid cancer cells with RET C634W mutation are insensitive to motesanib, compared to wild-type RET. PMID 21422803 · Coxon et al., 2012 · Open in CIViC | civic |
| RET M918T1 | ||||||||
| Motesanib | Thyroid Gland Medullary CarcinomaALIAS | Predictive | D | Supports Resistance | 3 | accepted | EID76Medullary thyroid cancer cells with RET M918T mutation are insensitive to motesanib, compared to wild-type RET. PMID 21422803 · Coxon et al., 2012 · Open in CIViC | civic |